Ultrahuman Launches M2 Live in U.S. With Abbott Lingo™ CGM Integration
Advertisement
M2 Live is designed to stream glucose data directly into the Ultrahuman app, offering continuous metabolic insights supported by its analytics engine.
Ultrahuman has launched its M2 Live metabolic health platform in the United States, integrating glucose data from Abbott’s Lingo™ continuous glucose monitor (CGM). The launch is aimed at expanding access to real-time metabolic health tracking for health-conscious adults, including individuals with prediabetes, without requiring a prescription.
The platform is positioned as a more affordable entry point into metabolic monitoring, with CGM sensors available via subscription starting at $99 per month. M2 Live is designed to stream glucose data directly into the Ultrahuman app, offering continuous metabolic insights supported by its analytics engine.
Ultrahuman first introduced non-prescription CGM-based wellness tracking in 2021. With M2 Live, the company expands its metabolic health ecosystem, combining glucose tracking with broader physiological data to provide context-driven insights.
The platform integrates data from the Ultrahuman Ring, Blood Vision blood biomarker testing, and over 100 metabolic markers. These inputs are processed through Jade AI, Ultrahuman’s real-time biointelligence system, which correlates glucose fluctuations with sleep, stress, activity, and recovery patterns.
According to the company, M2 Live is designed to help users understand how lifestyle factors influence metabolic responses in real time. The system tracks glucose spikes, dietary responses, and activity-linked fuel utilization, while offering scoring systems such as Metabolic Score, Food Score, and Fueling Score to quantify metabolic performance.
Ultrahuman stated that only a small fraction of U.S. adults are metabolically healthy, highlighting the rising burden of chronic conditions such as Type 2 diabetes and cardiovascular disease. The platform is intended to provide continuous visibility into metabolic patterns that may support lifestyle adjustments related to diet, sleep, and physical activity.
The company also operates OGDb, described as a large open glucose database that aggregates anonymized user data to analyze food-related glucose responses across populations.
“M2 Live removes the friction of needing a physician for access to glucose data and insights,” said Hussain Ahamed, who leads strategic partnerships in the Americas at Ultrahuman.
Ultrahuman said its metabolic scoring system has been validated through multi-site clinical studies and peer-reviewed research, including work published in Nature and collaborations with institutions such as Stanford University and the Mayo Clinic.
The platform is expected to be available in the U.S. in the coming weeks via ultrahuman.com. Each Lingo biosensor is designed for up to 14 days of use, depending on individual wear conditions.
Stay tuned for more such updates on Digital Health News
